Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iBEST-1: TOBI Podhaler in Non-CF Bronchiectasis
NCT02712983Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of tobramycin in Non-cystic fibrosis bronchiectasis (NCFB), Pseudomonas aeruginosa infection, sponsored by Novartis. Started Feb 2017; status: completed.
02
Drugs
tobramycin
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02712983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712983.